ELV/COBI/FTC/TAF
ApprovedSmall molecule
ELV/COBI/FTC/TAF is one of 36 small molecule programs targeting Neurotoxicity. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
50 competitors in Neurotoxicity
#DrugCompanyPhaseTrials
1Naropin
FFresenius Kabi Oncology Ltd.
Approved
Marcaine
IInnocoll
Approved
Eloxatin
TevaPhase 3
Methylcobalamin
EisaiApproved
Epsom Salt
FFresenius Kabi Oncology Ltd.
Phase 3
Calcium Gluconate
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Wellcovorin
GGlaxo Dba Glaxosmithkline
Phase 3
Glutamine
SanofiPhase 3
Mecobalamin
EisaiPhase 3
Yescarta
GileadPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Neurotoxicity1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ELV/COBI/FTC/TAF. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- FFundacion SEIMC-GESIDA